chlamydia trachomatis, Neisseria gonorrhoeae. Trichomonas vaginalis and mycoplasma genitalium are inadequate. Meanwhile molecular biology-based methods for the identification of these organisms offer significant advantages. Yet, the acceptance of these molecular tests has been delayed due to their higher cost which is beyond the reach of national health care budgets and by the lack of a molecular test for gonococall antibiotic resistance.
Inherent in a molecular technique called the polymerase chain reaction (PCR) is the ability to combine related assays into a single multplex reaction with little increase in cost.
This application proposes the development of a multiplex PCR test for the above noted organisms thereby reducing the cost of each component assay to a cost comparable with conventional technologies. Further, the first multiplex PCR will be combined with a second designed to detect four genes/mutations responsible for antibiotic resistance in N. gonorrhoeae, thereby increasing the clinical utility of these tests. Both multiplex reactions will be designed with a fluorometric analysis system to facilitate their execution in an automated format.
Funding SchemeCSC - Cost-sharing contracts